RSS-Feed abonnieren
Bitte kopieren Sie die angezeigte URL und fügen sie dann in Ihren RSS-Reader ein.
https://www.thieme-connect.de/rss/thieme/de/10.1055-s-00000025.xml
PDF herunterladen
Horm Metab Res 2020; 52(08): 562-577
DOI: 10.1055/a-1089-7870
DOI: 10.1055/a-1089-7870
Review
Updates on the Management of Thyroid Cancer
Funding Information Intramural NIDDK funding ZIE DK 047053–12.
Abstract
The diagnostic modalities, stratification tools, and treatment options for patients with thyroid cancer have rapidly evolved since the development of the American Thyroid Association (ATA) guidelines in 2015. This review compiles newer concepts in diagnosis, stratification tools and treatment options for patients with differentiated thyroid cancer (DTC), medullary thyroid carcinoma (MTC) and anaplastic thyroid cancer (ATC). Newer developments apply precision medicine in thyroid cancer patients to avoid over-treatment in low risk disease and under-treatment in high risk disease. Among novel patient-tailored therapies are selective RET inhibitors that have shown efficacy in the treatment of MTC with limited systemic toxicity compared with non-specific tyrosine kinase inhibitors. The combination of BRAF and MEK inhibitors have revolutionized management of BRAF V600E mutant ATC. Several immunotherapeutic agents are being actively investigated in the treatment of all forms of thyroid cancer. In this review, we describe the recent advances in the diagnosis and management of DTC, MTC, and ATC, with an emphasis on novel treatment modalities.
Publikationsverlauf
Eingereicht: 03. August 2019
Angenommen: 19. Dezember 2019
Artikel online veröffentlicht:
10. Februar 2020
© Georg Thieme Verlag KG
Stuttgart · New York
-
References
- 1 Fagin JA, Wells SA. Biologic and clinical perspectives on thyroid cancer. New England Journal of Medicine 2016; 375: 1054-1067
- 2 Goudie C, Hannah-Shmouni F, Kavak M. et al. 65 Years of the Double Helix: Endocrine tumour syndromes in children and adolescents. Endocr Relat Cancer 2018; 25: T221-T244
- 3 Lim H, Devesa SS, Sosa JA. et al. Trends in thyroid cancer incidence and mortality in the United States, 1974–2013. JAMA 2017; 317: 1338-1348
- 4
Siegel RL,
Miller KD,
Jemal A.
Cancer statistics, 2018. CA Cancer J Clin 2018; 68: 7-30
MissingFormLabel
- 5 Tuttle RM, Haugen B, Perrier ND. Updated American Joint Committee on Cancer/Tumor-Node-Metastasis Staging System for Differentiated and Anaplastic Thyroid Cancer (8th Edition): What Changed and Why?. Thyroid 2017; 27: 751-756
- 6
Haugen BR,
Alexander EK,
Bible KC.
et al. 2015 American Thyroid Association management guidelines for adult patients
with
thyroid nodules and differentiated thyroid cancer: The American Thyroid
Association guidelines task force on thyroid nodules and differentiated thyroid
cancer. Thyroid 2016; 26: 1-133
MissingFormLabel
- 7 Wells SA, Asa SL, Dralle H. et al. Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma: The American Thyroid Association Guidelines Task Force on medullary thyroid carcinoma. Thyroid 2015; 25: 567-610
- 8 Smallridge RC, Ain KB, Asa SL. et al. American Thyroid Association guidelines for management of patients with anaplastic thyroid cancer. Thyroid 2012; 22: 1104-1139
- 9 Thompson LD. Ninety-four cases of encapsulated follicular variant of papillary thyroid carcinoma: A name change to noninvasive follicular thyroid neoplasm with papillary-like nuclear features would help prevent overtreatment. Modern Pathol 2016; 29: 698
- 10 Agrawal N, Akbani R, Aksoy BA. et al. Integrated genomic characterization of papillary thyroid carcinoma. Cell 2014; 159: 676-690
- 11 Nikiforova MN, Lynch RA, Biddinger PW. et al. RAS point mutations and PAX8-PPARγ rearrangement in thyroid tumors: Evidence for distinct molecular pathways in thyroid follicular carcinoma. J Clin Endocrinol Metab 2003; 88: 2318-2326
- 12 Hulse K, Williamson A, Gibb FW. et al. Evaluating the predicted impact of changes to the AJCC/TMN staging system for differentiated thyroid cancer (DTC): A prospective observational study of patients in South East Scotland. Clin Otolaryngol 2019; 44: 330-335
- 13 Lamartina L, Grani G, Arvat E. et al. 8th edition of the AJCC/TNM staging system of thyroid cancer: what to expect (ITCO#2). Endocr Relat Cancer 2018; 25: L7-Ll11
- 14 Lamartina L, Grani G, Durante C. et al. Recent advances in managing differentiated thyroid cancer. F1000Res 2018; 7: 86
- 15 Shaha AR, Migliacci JC, Nixon IJ. et al. Stage migration with the new American Joint Committee on Cancer (AJCC) staging system (8th edition) for differentiated thyroid cancer. Surgery 2019; 165: 6-11
- 16 Vaisman F, Tuttle RM. Clinical Assessment and Risk Stratification in Differentiated Thyroid Cancer. Endocrinol Metab Clin North Am 2019; 48: 99-108
- 17
Haugen BR,
Alexander EK,
Bible KC.
et al. 2015 American Thyroid Association Management Guidelines for Adult Patients
with
Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid
Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid
Cancer. Thyroid 2016; 26: 1-133
MissingFormLabel
- 18 Tuttle RM, Alzahrani AS. Risk Stratification in Differentiated Thyroid Cancer: From Detection to Final Follow-up. J Clin Endocrinol Metab 2019; pii jc.2019-00177
- 19 Kim M, Kim BH, Kim JM. et al. Concordance in postsurgical radioactive iodine therapy recommendations between Watson for oncology and clinical practice in patients with differentiated thyroid carcinoma. Cancer 2019; 125: 2803-2809
- 20 Yang Y, Shen X, Li R. et al. The detection and significance of EGFR and BRAF in cell-free DNA of peripheral blood in NSCLC. Oncotarget 2017; 8: 49773
- 21 Fussey JM, Bryant JL, Batis N. et al. The clinical utility of cell-free DNA measurement in differentiated thyroid cancer: A systematic review. Front Oncol 2018; 8: 132
- 22 Kim BH, Kim IJ, Lee BJ. et al. Detection of plasma BRAF(V600E) mutation is associated with lung metastasis in papillary thyroid carcinomas. Yonsei Med J 2015; 56: 634-640
- 23 Sandulache VC, Williams MD, Lai SY. et al. Real-Time Genomic Characterization utilizing circulating cell-free DNA in patients with anaplastic thyroid carcinoma. Thyroid 2017; 27: 81-87
- 24 Cote GJ, Evers C, Hu MI. et al. Prognostic Significance of Circulating RET M918T Mutated Tumor DNA in Patients With Advanced Medullary Thyroid Carcinoma. J Clin Endocrinol Metab 2017; 102: 3591-3599
- 25 Khatami F, Tavangar SM. Liquid biopsy in thyroid cancer: New insight. Int J Hematol Oncol Stem Cell Res 2018; 12: 235
- 26 Fussey JM, Bryant JL, Batis N. et al. the clinical Utility of cell-Free DNa measurement in differentiated thyroid cancer: a systematic review. Front Oncol 2018; 8: 132
- 27 Zambeli-Ljepović A, Wang F, Dinan MA. et al. Extent of surgery for low-risk thyroid cancer in the elderly: Equipoise in survival but not in short-term outcomes. Surgery 2019; 166: 895-900
- 28 Liu Z, Zhao Q, Liu C. et al. Is biopsy enough for papillary thyroid microcarcinoma?: An analysis of the SEER database 2004–2013 with propensity score matching. Medicine (Baltimore) 2018; 97: e11791
- 29 Sakai T, Sugitani I, Ebina A. et al. Active surveillance for T1bN0M0 papillary thyroid carcinoma. Thyroid 2019; 29: 59-63
- 30 Brito JP, Ito Y, Miyauchi A. et al. A clinical framework to facilitate risk stratification when considering an active surveillance alternative to immediate biopsy and surgery in papillary microcarcinoma. Thyroid 2016; 26: 144-149
- 31 Tuttle RM, Zhang L, Shaha A. A clinical framework to facilitate selection of patients with differentiated thyroid cancer for active surveillance or less aggressive initial surgical management. Exp Rev Endocrinol Metab 2018; 13: 77-85
- 32 Tuttle RM, Fagin JA, Minkowitz G. et al. Natural history and tumor volume kinetics of papillary thyroid cancers during active surveillance. JAMA Otolaryngol Head Neck Surgery 2017; 143: 1015-1020
- 33 Miyauchi A, Ito Y. Conservative Surveillance Management of Low-Risk Papillary Thyroid Microcarcinoma. Endocrinol Metab Clin 2019; 48: 215-226
- 34 Zanocco KA, Hershman JM, Leung AM. Active Surveillance of Low-Risk Thyroid Cancer. JAMA 2019; 321: 2020-2021
- 35 Brito JP, Moon JH, Zeuren R. et al. Thyroid cancer treatment choice: a pilot study of a tool to facilitate conversations with patients with papillary microcarcinomas considering treatment options. Thyroid 2018; 28: 1325-1331
- 36 Ito Y, Miyauchi A. Active surveillance as first-line management of papillary microcarcinoma. Ann Rev Med 2019; 70: 369-379
- 37 Davies L, Roman BR, Fukushima M. et al. Patient experience of thyroid cancer active surveillance in Japan. JAMA Otolaryngol Head Neck Surgery 2019; 145: 363-370
- 38 Tuttle RM, Ahuja S, Avram AM. et al. Controversies, Consensus, and Collaboration in the Use of (131)I Therapy in Differentiated Thyroid Cancer: A Joint Statement from the American Thyroid Association, the European Association of Nuclear Medicine, the Society of Nuclear Medicine and Molecular Imaging, and the European Thyroid Association. Thyroid 2019; 29: 461-470
- 39 Durante C, Haddy N, Baudin E. et al. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J Clin Endocrinol Metab 2006; 91: 2892-2899
- 40 Coelho SM, Corbo R, Buescu A. et al. Retinoic acid in patients with radioiodine non-responsive thyroid carcinoma. J Endocrinol Invest 2004; 27: 334-339
- 41 Liu Y, Van Der Pluijm G, Karperien M. et al. Lithium as adjuvant to radioiodine therapy in differentiated thyroid carcinoma: Clinical and in vitro studies. Clin Endocrinol 2006; 64: 617-624
- 42 Ho AL, Grewal RK, Leboeuf R. et al. Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer. N Eng J Med 2013; 368: 623-632
- 43 Durante C, Puxeddu E, Ferretti E. et al. BRAF mutations in papillary thyroid carcinomas inhibit genes involved in iodine metabolism. J Clin Endocrinol Metab 2007; 92: 2840-2843
- 44 Liu D, Hu S, Hou P. et al. Suppression of BRAF/MEK/MAP kinase pathway restores expression of iodide-metabolizing genes in thyroid cells expressing the V600E BRAF mutant. Clin Cancer Res 2007; 13: 1341-1349
- 45 Ho AL, Grewal RK, Leboeuf R. et al. Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer. N Eng J Med 2013; 368: 623-632
- 46 Brown SR, Hall A, Buckley HL. et al. Investigating the potential clinical benefit of Selumetinib in resensitising advanced iodine refractory differentiated thyroid cancer to radioiodine therapy (SEL-I-METRY): Protocol for a multicentre UK single arm phase II trial. BMC Cancer 2019; 19: 582
- 47 Wadsley J, Gregory R, Flux G. et al. SELIMETRY—a multicentre I-131 dosimetry trial: A clinical perspective. Br J Radiol 2017; 90: 20160637
- 48 Tumino D, Frasca F, Newbold K. Updates on the management of advanced, metastatic, and radioiodine refractory differentiated thyroid cancer. Front Endocrinol 2017; 8: 312
- 49 Brose MS, Nutting CM, Jarzab B. et al. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: A randomised, double-blind, phase 3 trial. Lancet (London, England) 2014; 384: 319-328
- 50 Schlumberger M, Tahara M, Wirth LJ. et al. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. The New England Journal of Medicine 2015; 372: 621-630
- 51 Haddad RI, Nasr C, Bischoff L. et al. NCCN guidelines insights: Thyroid carcinoma, version 2.2018. J Natl Comp Cancer Network 2018; 16: 1429-1440
- 52 Tuttle RM, Brose MS, Grande E. et al. Novel concepts for initiating multitargeted kinase inhibitors in radioactive iodine refractory differentiated thyroid cancer. Best Pract Res Clin Endocrinol Metab 2017; 31: 295-305
- 53 Ulisse S, Tuccilli C, Sorrenti S. et al. PD-1 ligand expression in epithelial thyroid cancers: potential clinical implications. Int J Mol Sci 2019; 20: 1405
- 54 Mehnert JM, Varga A, Brose MS. et al. Safety and antitumor activity of the anti–PD-1 antibody pembrolizumab in patients with advanced, PD-L1–positive papillary or follicular thyroid cancer. BMC Cancer 2019; 19: 196
- 55 Kim K, Jeon S, Kim T-M. et al. Immune gene signature delineates a subclass of papillary thyroid cancer with unfavorable clinical outcomes. Cancers 2018; 10: 494
- 56 Ries L, Eisner M, Kosary C. Trends in SEER incidence and US mortality using the joinpoint regression program 1975–2000 with up to three joinpoints by race and sexSEER [monografía en Internet]. In Bethesda: National Cancer Inst; www.seer.cancer.gov 2003
- 57 Elisei R, Romei C. Medullary Thyroid Cancer. In The Thyroid and Its Diseases. Berlin: Springer; 2019: 673-691
- 58 Hsiao SJ, Nikiforov YE. Molecular Genetics and Diagnostics of Thyroid Cancer. In: The Thyroid and Its Diseases. Berlin: Springer; 2019: 549-561
- 59 Agrawal N, Jiao Y, Sausen M. et al. Exomic sequencing of medullary thyroid cancer reveals dominant and mutually exclusive oncogenic mutations in RET and RAS. J Clin Endocrinol Metab 2013; 98: E364-E369
- 60 de Groot JWB, Links TP, Plukker JT. et al. RET as a diagnostic and therapeutic target in sporadic and hereditary endocrine tumors. Endocr Rev 2006; 27: 535-560
- 61 Eng C, SmIth DP, MullIgan LM. et al. Point mutation within the tyrosine kinase domain of the RET proto-oncogene in multiple endocrine neoplasia type 2B and related sporadic tumours. Hum Mol Genet 1994; 3: 237-241
- 62 Elisei R, Romei C, Cosci B. et al. RET genetic screening in patients with medullary thyroid cancer and their relatives: Experience with 807 individuals at one center. J Clin Endocrinol Metab 2007; 92: 4725-4729
- 63 Wells SA, Robinson BG, Gagel RF. et al. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: A randomized, double-blind phase III trial. J Clin Oncol 2012; 30: 134
- 64 Verbeek HH, Alves MM, de Groot J-WB. et al. The effects of four different tyrosine kinase inhibitors on medullary and papillary thyroid cancer cells. J Clin Endocrinol Metab 2011; 96: E991-E995
- 65 Chen K, Gao Y, Shi F. et al. Apatinib-treated advanced medullary thyroid carcinoma: A case report. OncoTarg Therap 2018; 11: 459
- 66 De Groot J, Zonnenberg B, van Ufford-Mannesse PQ. et al. A phase II trial of imatinib therapy for metastatic medullary thyroid carcinoma. J Clin Endocrinol Metab 2007; 92: 3466-3469
- 67 Elisei R, Schlumberger MJ, Müller SP. et al. Cabozantinib in progressive medullary thyroid cancer. J Clin Oncol 2013; 31: 3639
- 68 Kurzrock R, Sherman SI, Ball DW. et al. Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer. J Clin Oncol 2011; 29: 2660
- 69 Lam ET, Ringel MD, Kloos RT. et al. Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer. J Clin Oncol 2010; 28: 2323
- 70 Robinson BG, Paz-Ares L, Krebs A. et al. Vandetanib (100 mg) in patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Endocrinol Metab 2010; 95: 2664-2671
- 71 Schlumberger M, Jarzab B, Cabanillas ME. et al. A phase II trial of the multitargeted tyrosine kinase inhibitor lenvatinib (E7080) in advanced medullary thyroid cancer. Clin Cancer Res 2016; 22: 44-53
- 72 Schlumberger MJ, Elisei R, Bastholt L. et al. Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer. J Clin Oncol 2009; 27: 3794-3801
- 73 Sherman SI, Cohen EE, Schoffski P. et al. Efficacy of cabozantinib (Cabo) in medullary thyroid cancer (MTC) patients with RAS or RET mutations: Results from a phase III study. J Clin Oncol 2013; 31
- 74 Wells SA, Gosnell JE, Gagel RF. et al. Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Oncol 2010; 28: 767
- 75 Pennell NA, Daniels GH, Haddad RI. et al. A phase II study of gefitinib in patients with advanced thyroid cancer. Thyroid 2008; 18: 317-323
- 76 Carr LL, Mankoff DA, Goulart BH. et al. Phase II study of daily sunitinib in FDG-PET–positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation. Clin Cancer Res 2010; 16: 5260-5268
- 77 Cohen EE, Rosen LS, Vokes EE. et al. Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: Results from a phase II study. J Clin Oncol 2008; 26: 4708
- 78 Locati LD, Licitra L, Agate L. et al. Treatment of advanced thyroid cancer with axitinib: Phase 2 study with pharmacokinetic/pharmacodynamic and quality-of-life assessments. Cancer 2014; 120: 2694-2703
- 79 Bible KC, Suman VJ, Molina JR. et al. A multicenter phase 2 trial of pazopanib in metastatic and progressive medullary thyroid carcinoma: MC057H. J Clin Endocrinol Metab 2014; 99: 1687-1693
- 80 La Pietra V, Sartini S, Botta L. et al. Challenging clinically unresponsive medullary thyroid cancer: Discovery and pharmacological activity of novel RET inhibitors. Eur J Med Chem 2018; 150: 491-505
- 81 Subbiah V, Velcheti V, Tuch B. et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol 2018; 29: 1869-1876
- 82 Drilon AE, Subbiah V, Oxnard GR. et al. A phase 1 study of LOXO-292, a potent and highly selective RET inhibitor, in patients with RET-altered cancers. J Clin Oncol 2018; 36
- 83 Subbiah V, Gainor JF, Rahal R. et al. Precision targeted therapy with BLU-667 for RET-driven cancers. Cancer Discov 2018; 8: 836-849
- 84 Subbiah V, Taylor M, Lin J. et al. Highly potent and selective RET inhibitor, BLU-667, achieves proof of concept in ARROW, a phase 1 study of advanced, RET-altered solid tumors. American Association for Cancer Research Annual Meeting. 2018 Abstract CT043
- 85 Rao SN, Cabanillas ME. Navigating systemic therapy in advanced thyroid carcinoma: from standard of care to personalized therapy and beyond. J Endocr Soc 2018; 2: 1109-1130
- 86 French JD, Bible K, Spitzweg C. et al. Leveraging the immune system to treat advanced thyroid cancers. Lancet Diabetes Endocrinol 2017; 5: 469-481
- 87 Schott M, Seissler J, Lettmann M. et al. Immunotherapy for medullary thyroid carcinoma by dendritic cell vaccination. J Clin Endocrinol Metab 2001; 86: 4965-4969
- 88 Bachleitner-Hofmann T, Friedl J, Hassler M. et al. Pilot trial of autologous dendritic cells loaded with tumor lysate (s) from allogeneic tumor cell lines in patients with metastatic medullary thyroid carcinoma. Oncol Rep 2009; 21: 1585-1592
- 89 Bilusic M, Heery CR, Arlen PM. et al. Phase I trial of a recombinant yeast-CEA vaccine (GI-6207) in adults with metastatic CEA-expressing carcinoma. Cancer Immunol Immunother 2014; 63: 225-234
- 90 Iten F, Müller B, Schindler C. et al. Response to [90Yttrium-DOTA]-TOC treatment is associated with long-term survival benefit in metastasized medullary thyroid cancer: A phase II clinical trial. Clin Cancer Res 2007; 13: 6696-6702
- 91 Vaisman F, de Castro PHR. Lopes FPPL et al. Is there a role for peptide receptor radionuclide therapy in medullary thyroid cancer?. Clin Nucl Med 2015; 40: 123-127
- 92 Beukhof CM, Brabander T, van Nederveen FH. et al. Peptide receptor radionuclide therapy in patients with medullary thyroid carcinoma: predictors and pitfalls. BMC Cancer 2019; 19: 325
- 93 Keegan M, Wilcoxen K, Ho PT. BOS172738: A novel highly potent and selective RET kinase inhibitor in Phase 1 clinical development. AACR. 2019
- 94 Subbiah V, Kreitman RJ, Wainberg ZA. et al. Dabrafenib and trametinib treatment in patients with locally advanced or metastatic BRAF V600–mutant anaplastic thyroid cancer. J Clin Oncol 2018; 36: 7
- 95 Sosa JA, Elisei R, Jarzab B. et al. Randomized safety and efficacy study of fosbretabulin with paclitaxel/carboplatin against anaplastic thyroid carcinoma. Thyroid 2014; 24: 232-240
- 96 Akaishi J, Sugino K, Kitagawa W. et al. Prognostic factors and treatment outcomes of 100 cases of anaplastic thyroid carcinoma. Thyroid 2011; 21: 1183-1189
- 97 Kebebew E, Greenspan FS, Clark OH. et al. Anaplastic thyroid carcinoma: treatment outcome and prognostic factors. Cancer 2005; 103: 1330-1335
- 98 Cabanillas ME, Zafereo M, Gunn GB. et al. Anaplastic thyroid carcinoma: Treatment in the age of molecular targeted therapy. J Oncol Pract 2016; 12: 511-518
- 99 Cabanillas ME, Zafereo M, Williams MD. et al. Recent advances and emerging therapies in anaplastic thyroid carcinoma. F1000Research. 2018 7. (F1000 Faculty Rev): 87; https://doi.org/10.12688/f1000research.13124.1
- 100 Hyman DM, Puzanov I, Subbiah V. et al. Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations. N Eng J Med 2015; 373: 726-736
- 101 Lim S, Chang H, Yoon M. et al. A multicenter, phase II trial of everolimus in locally advanced or metastatic thyroid cancer of all histologic subtypes. Ann Oncol 2013; 24: 3089-3094
- 102 Lorch JH, Busaidy N, Ruan DT. et al. A phase II study of everolimus in patients with aggressive RAI refractory (RAIR) thyroid cancer (TC). J Clin Oncol 2013; 31
- 103 Chintakuntlawar AV, Rumilla KM, Smith CY. et al. Expression of PD-1 and PD-L1 in anaplastic thyroid cancer patients treated with multimodal therapy: Results from a retrospective study. J Clin Endocrinol Metab 2017; 102: 1943-1950
- 104 Kollipara R, Schneider B, Radovich M. et al. Exceptional response with immunotherapy in a patient with anaplastic thyroid cancer. Oncologist 2017; 22: 1149-1151
- 105 Iyer PC, Dadu R, Gule-Monroe M. et al. Salvage pembrolizumab added to kinase inhibitor therapy for the treatment of anaplastic thyroid carcinoma. J Immunother Cancer 2018; 6: 68
- 106 Choi YJ, Baek JH, Park HS. et al. A computer-aided diagnosis system using artificial intelligence for the diagnosis and characterization of thyroid nodules on ultrasound: initial clinical assessment. Thyroid 2017; 27: 546-552
- 107 Diggans J, Kim SY, Hu Z. et al. Machine learning from concept to clinic: reliable detection of braf v600e DNA mutations in thyroid nodules using high-dimensional RNA expression data. In, Pacific Symposium on Biocomputing Co-Chairs: World Sci 2014; 371-382
- 108 Gubbi S, Hamet P, Tremblay J. et al. Artificial Intelligence and Machine Learning in Endocrinology and Metabolism: The Dawn of a New Era. Front Endocrinol 2019; 10: 185
- 109 Hu S, Liao Y, Chen L. Identification of key pathways and genes in anaplastic thyroid carcinoma via integrated bioinformatics analysis. Med Sci Monit 2018; 24: 6438
- 110 Wildman-Tobriner B, Buda M, Hoang JK. et al. Using Artificial Intelligence to Revise ACR TI-RADS Risk Stratification of Thyroid Nodules: Diagnostic Accuracy and Utility. Radiology 2019; 292: 112-119